JNCI Journal of the National Cancer Institute · 1998 · 204 citations · 24 references
MedicineGeneticsOncologyDna RepairMolecular OncologyRadiobiologyDna Damage SignalingDna Repair DefectsDna Strand BreaksDouble-strand Break RepairRadiation CarcinogenesisRadiation TherapyBrca MutationsBrca2 DeficiencyBrca2 FunctionBrca2 InactivationDouble-strand Dna BreaksRadiation Sensitivity Assays
BACKGROUND: The protein product of the BRCA2 gene mediates repair of double-strand breaks in DNA. Because a number of cancer therapies exert cytotoxic effects via the initiation of double-strand breaks, cancers comprised of cells carrying BRCA2 gene mutations may be more amenable to treatment with agents that cause such breaks. METHODS: We identified a human pancreatic adenocarcinoma cell line lacking one copy of the BRCA2 gene and containing a mutation (6174delT) in the remaining copy. In vitro and in vivo experiments were conducted with this cell line and with other carcinoma cell lines matched for similar genetic mutations, similar differentiation status, and/or similar carcinoma type to examine double-strand break repair, sensitivity to drugs that induce double-strand breaks, and radiation sensitivity. RESULTS: BRCA2-defective cells were unable to repair the double-strand DNA breaks induced by ionizing radiation. These cells were also markedly sensitive to mitoxantrone, amsacrine, and etoposide (drugs that induce double-strand breaks) (two-sided P = .002) and to ionizing radiation (two-sided P = .001). Introduction of antisense BRCA2 deoxyribonucleotides into cells possessing normal BRCA2 function led to increased sensitivity to mitoxantrone (two-sided P = .008). Tumors formed by injection of BRCA2-defective cells into nude mice were highly sensitive (>90% tumor size reduction, two-sided P = .002) to both ionizing radiation and mitoxantrone when compared with tumors exhibiting normal BRCA2 function. Histologic analysis of irradiated BRCA2-defective tumors showed a large degree of necrosis compared with that observed for control tumors possessing normal BRCA2 function. CONCLUSION: BRCA2-defective cancer cells are highly sensitive to agents that cause double-strand breaks in DNA.
24
Goodman and Gilman's the Pharmacological Basis of Therapeutics
William H. Stigelman, D Pharm · Military Medicine · 1986 · 6.8K citations
Identification of the breast cancer susceptibility gene BRCA2
Richard Wooster, Graham R. Bignell, Jonathan Lancaster et al. · Nature · 1995 · 3.7K citations
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
Shyam K. Sharan, Masami Morimatsu, Urs Albrecht et al. · Nature · 1997 · 1.1K citations · Full text
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Sean V. Tavtigian, Jacques Simard, Johanna M. Rommens et al. · Nature Genetics · 1996 · 844 citations
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Mieke Schutte, Ralph H. Hruban, Joseph Geradts et al. · PubMed · 1997 · 665 citations